Nvidia-backed Iambic Therapeutics files for U.S. IPO
Iambic Therapeutics, backed by NVIDIA, filed for a U.S. initial public offering and plans to list on Nasdaq under the ticker IAM.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
5 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
UK's Oxford BioMedica H1 revenue rises on increased manufacturing
(This story was generated using AI and automation, please see disclaimer ) Overview UK cell and gene therapy CDMO's H1 revenue rose 9% yr/yr, matching analyst estimate Adjusted operating EBITDA loss narrowed to £2.5 mln from £3.9 mln a year earlier Gross margin fell to 37% from 43% due to product and client mix changes
Iambic Therapeutics files for an IPO
Iambic Therapeutics, Inc. files for an IPO, according to TradingView News.
Iambic Therapeutics files for US IPO
Life sciences company Iambic Therapeutics filed for an initial public offering in the US on Monday.
Iambic Therapeutics files for US IPO
Iambic Therapeutics filed for an initial public offering in the US on Monday.